Letztes “update” :
26/03/2024
Antikrebsmittel   Cisplatin  
Injektion
Stabilität der Lösung Gemengestabilität Stabilitätbeeinflussende Faktoren Kompatibilitäten Applikationsart Literaturverzeichnis Pdf
   Chemische Struktur  

Handelsmarke   Handelsmarke     

Handelsnamen sind als beispielhaft anzusehen. Sonstige Bestandteile können je nach Hersteller oder Land verschieden sein

Abiplatin Südafrika
Accocit Mexiko
Briplatin Japan
Cisplatex Brasilien
Cisplatin Australien, Belgien, Kanada, Österreich, Saudi-Arabien
Cisplatina Brasilien
Cisplatine Belgien, Frankreich
Cisplatyl Frankreich, Griechenland, Saudi-Arabien, Türkei
Citoplatino Argentinien, Italien
Citoplax Brasilien
Corsis Mexiko
Insel Brasilien
Neoplatin Spanien
Pamifect Indien
Placis Spanien, Türkei
Platamine Griechenland, Italien, Marokko, Tunesien
Platanovag Argentinien
Platiblastin Österreich
Platidiam Polen, Ungarn
Platinex Deutschland, Großbritannien, Italien
Platinol Belgien, Dänemark, Finnland, Griechenland, Luxemburg, Mexiko, Niederlande, Österreich, Schweden, Schweiz, Vereinigte Staaten von Amerika
Platistil Spanien
Platistine Belgien, Brasilien, Luxemburg
Platosin Ägypten, Belgien, Griechenland, Japan, Niederlande, Rumänien, Türkei, Venezuela
Pronto Platamine Italien
Zuridry Mexiko
Literaturverzeichnis   Injektion   Literaturverzeichnis : Cisplatin  
Typ Veröffentlichung
3 Zeitung Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
53 Zeitung Henry DW, Marshall JL, Nazzar OD, Fox JL, Leff RD.
Stability of cisplatin and ondansetron hydrochloride in admixtures for continuous infusion.
Am J Health-Syst Pharm 1995 ; 52: 2570-2573.
57 Zeitung Mayron D, Gennaro AR.
Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs.
Am J Health-Syst Pharm 1996 ; 53: 294-304.
81 Zeitung Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 Zeitung Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
85 Zeitung Trissel LA, Bready BB.
Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 1716-1719.
91 Zeitung Lober CA, Dollard PA.
Visual compatibility of gallium nitrate with selected drugs during Y-site injection.
Am J Hosp Pharm 1993 ; 50: 1208-1210.
99 Zeitung Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
147 Zeitung Pujol Cubells M, Prat Aixela J, Girona Brumos V, Duran Pou S, Villaronga Flaque MV.
Stability of cisplatin in sodium chloride 0.9% intravenous solution related to the container’s material.
Pharm World Sci 1993 ; 15: 34-36.
149 Zeitung Rochard E, Barthes D, Courtois P.
Stability of cisplatin in ethylene vinylacetate portable infusion-pump reservoirs.
J Clin Pharm Ther 1992 ; 17: 315-318.
164 Zeitung Benaji B, Dine T, Luyckx M, Brunet C, Goudaliez F, Mallevais ML, Cazin M, Gressier B, Cazin JC.
Stability and compatibility of cisplatin and carboplatin with PVC infusion bags.
J Clin Pharm Ther 1994 ; 19: 95-100.
169 Zeitung Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
244 Zeitung Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249 Zeitung Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 Zeitung Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
300 Zeitung Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 Zeitung Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307 Zeitung Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
331 Zeitung Marquardt ED.
Visual compatibility of hydroxyzine hydrochloride with various antineoplasic agents.
Am J Hosp Pharm 1988 ; 45: 2127.
334 Zeitung Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 Zeitung Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
409 Zeitung Cheung YW, Cradock JC, Vishnuvajjala BR, Flora KP.
Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions.
Am J Hosp Pharm 1987 ; 44: 124-130.
410 Zeitung Zieske PA, Koberda M, Hines JL, Knight CC, Sriram R, Raghavan NV, Rabinow BE.
Characterization of cisplatin degradation as affected by pH and light.
Am J Hosp Pharm 1991 ; 48: 1500-1506.
413 Zeitung Stewart CF, Fleming RA.
Compatibility of cisplatin and fluorouracil in 0.9% sodium chloride injection.
Am J Hosp Pharm 1990 ; 47: 1373-1377.
417 Zeitung Stewart CF, Hampton EM.
Stability of cisplatin and etoposide in intravenous admixtures.
Am J Hosp Pharm 1989 ; 46: 1400-1404.
492 Zeitung Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
660 Zeitung Michaels MR, Stauffer GL, Haas DP.
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Ann Pharmacotherapy 1996 ; 30: 228-232.
742 Zeitung Greene RF, Chatterji DC, Hiranaka PK, Gallelli JF.
Stability of cisplatin in aqueous solution.
Am J Hosp Pharm 1979 ; 36: 38-43.
855 Zeitung Hrubisko M, Mc Gown AT, Prendiville JA, Radford JA, Thatcher N, Fox BW.
Suitability of cisplatin solutions for 14-day continuous infusion by ambulatory pump.
Cancer Chemother Pharmacol 1992 ; 29: 252-255.
872 Zeitung Zhang YP, Xu QA, Trissel LA, Gilbert DL, Martinez F.
Compatibility and stability of paclitaxel combined with cisplatin and with carboplatin in infusion solutions.
Ann Pharmacotherapy 1997 ; 31: 1465-1470.
905 Zeitung Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921 Zeitung Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1026 Zeitung Mayron D, Gennaro AR.
Stability and compatibility of topotecan hydrochloride with selected drugs.
Am J Health-Syst Pharm 1999 ; 56: 875-881.
1080 Zeitung La Folette JM, Arbus MH, Lauper RD.
Stability of cisplatin admixtures in polyvinyl chloride bags.
Am J Hosp Pharm 1985 ; 42: 2652.
1410 Zeitung Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 Zeitung Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 Zeitung Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1496 Zeitung Trissel LA, Martinez JF, Gilbert DL.
Screening cladribine for Y-site physical compatibility with selected drugs.
Hosp Pharm 1996 ; 31: 1425-1428.
1625 Zeitung Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1729 Zeitung Mittner A, Vincze Z, Jemnitz K.
Stability of cisplatin containing infusion.
Pharmazie 1998 ; 53: 490-492.
1925 Zeitung Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1950 Zeitung Trissel LA, Yanping Z.
Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin and oxaliplatin during simulated Y-site administration.
J Oncol Pharm Practice 2004 ; 10: 191-195.
1953 Zeitung Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982 Zeitung Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2247 Zeitung Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262 Zeitung Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3183 Zeitung Sewell G
Physical and chemical stability of cisplatin infusions in PVC containers.
EJOP 2010 ; 4, 3: 11-13.
3474 Labor Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009
3574 Labor Ondansetron - Résumé des caractéristiques du produit
Accord Healthcare France SAS 2013
3578 Labor Cisplatin - Summary of Product Characteristics
Accord Healthcare 2011
3602 Labor Mesna (Uromitexan®)- Summary of Product Characteristics
Baxter SAS 2013
3670 Zeitung Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30.
4084 Labor Cisplatine - Résumé des caractéristiques du produits
Accord Health Care 2017
4137 Zeitung Patel T, Sewell G.
Short Report : Extended Stability Studies on Bortezomib Injection and Infusions of Cisplatin and Pemetrexed (all Accord Healthcare).
Newsletter Stabilis 2018 41;2-6
4589 Labor Pemetrexed Mylan - Résumé des caractéristiques du produit
Mylan 2021

  Mentions Légales